SR One Capital Management, LP
Redwood City, CA · CIK 1910264 · 13F filing filed 2026-08-12
SEC-registered investment adviser since 2020 · limited partnership
- Assets managed$2.4bn
- Staff28 · 15 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds19 · $2.4bn gross assets
- Websitesrone.com
- Form ADV · 2026-03-31SEC adviser record
$1.0bn
reported value
+13.5% vs Q1 2026
15positions
95.1%in top 10
3 new
1 added
0 reduced
2 sold out
vs Q1 2026
Holdings, Q2 2026
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| VERADERMICS INC MANE | $295.3m28.42% | Unchanged |
| ZENAS BIOPHARMA INC ZBIO | $127.9m12.31% | Unchanged |
| CRISPR THERAPEUTICS AG CRSP | $111.2m10.70% | Unchanged |
| AVALYN PHARMACEUTICALS INC AVLN | $108.9m10.48% | New |
| DESIGN THERAPEUTICS INC DSGN | $94.4m9.09% | Unchanged |
| ODYSSEY THERAPEUTICS INC ODTX | $71.0m6.83% | New |
| ALUMIS INC ALMS | $55.2m5.31% | Unchanged |
| ORIC PHARMACEUTICALS INC ORIC | $50.0m4.81% | Added +100.5k |
| MINERALYS THERAPEUTICS INC MLYS | $42.2m4.06% | Unchanged |
| ARS PHARMACEUTICALS INC SPRY | $32.1m3.09% | Unchanged |
| MOBIA MED INC MOBI | $26.6m2.56% | New |
| NKARTA INC NKTX | $9.4m0.91% | Unchanged |
| OCULIS HOLDING AG OCS | $8.9m0.86% | Unchanged |
| ULTRAGENYX PHARMACEUTICAL IN RARE | $4.6m0.44% | Unchanged |
| ENGENE HOLDINGS INC COM | $1.3m0.12% | Unchanged |
Sold out since Q1 2026
| Security | Value then |
|---|---|
| ARCELLX INC ACLX | $269.4m2.3m shares |
| ORUKA THERAPEUTICS INC ORKA | $21.1m430.3k shares |